Back to Gastroenterology
Gastroenterologyv2007Evidence-Based

NAFLD (Non-Alcoholic Fatty Liver Disease) Fibrosis Score

Estimates amount of scarring in the liver based on various lab tests. Distinguishes between patients with nonalcoholic fatty liver disease who have (F3-F4) and do not have (F0-F2) advanced fibrosis.

Clinical Input Parameters

years
Range: 0 — 120 years
kg/m²
Range: 10 — 70 kg/m²
IU/L
Range: 1 — 2000 IU/L
IU/L
Range: 1 — 2000 IU/L
×10⁹/L
Range: 10 — 800 ×10⁹/L
g/dL
Range: 1 — 6 g/dL
Clinical Assessment
Awaiting Parameters
nafld fibrosis score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The NAFLD (Non-Alcoholic Fatty Liver Disease) Fibrosis Score is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within gastroenterology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

NAFLD Score = -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m²) + 1.13 × hyperglycemia (yes=1, no=0) + 0.99 × AST/ALT ratio - 0.013 × platelet count (×10⁹/L) - 0.66 × albumin (g/dL)

Clinical Pearls & Practice Notes

  • Fibrosis stages: F0 = absence of fibrosis, F1 = perisinusoidal or periportal fibrosis, F2 = perisinusoidal and portal/periportal fibrosis, F3 = bridging fibrosis, F4 = cirrhosis
  • The score was developed based on 733 patients with biopsy-proven NAFLD
  • AUROC for detecting advanced fibrosis was 0.88 (95% CI 0.85-0.92)
  • Approximately 30% of patients may fall into the indeterminate range requiring additional testing
  • The score helps reduce the need for liver biopsy by identifying patients likely or unlikely to have advanced fibrosis

Evidence & Literature Citations

  1. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007 Apr;45(4):846-54. doi: 10.1002/hep.21496.
  2. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010 Sep;59(9):1265-9. doi: 10.1136/gut.2010.216077.

Score Interpretation Ranges

F0-F2-10 – -1.455 pts

Absence of significant fibrosis

Indeterminate-1.455 – 0.676 pts

Indeterminate zone

F3-F40.676 – 10 pts

Presence of significant fibrosis

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.